US Patent 10398654 Pharmaceutical compositions
Patent 10398654 was granted and assigned to Boehringer Ingelheim on September, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+266 characters)
Article
Patent abstract
The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 26 Apr, 2023
Golden AI
Infobox
Edits on 27 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
103986540
Date of Patent
September 3, 2019
0Patent Application Number
159064140
Date Filed
February 27, 2018
0Official Website
Patent Citations
Patent Primary Examiner
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
103986540
Date of Patent
September 3, 2019
0Patent Application Number
159064140
Date Filed
February 27, 2018
0Official Website
Patent Citations
Patent Primary Examiner
Golden AI
Infobox
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 28 Jan, 2022
Golden AI
Edits made to:
Infobox (+10 properties)
US Patent 10398654 Pharmaceutical compositions
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10398654
Date of patent
September 3, 2019
Patent application number
15906414
Date Filed
February 27, 2018
Patent citations
Patent primary examiner
Find more entities like US Patent 10398654 Pharmaceutical compositions
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.